Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: Recommendations and rationale
Postmenopausal hormone replacement therapy for primary prevention of chronic conditions: Recommendations and rationale
复制标题
DOI：
10.7326/0003-4819-137-10-200211190-00013
复制
发表时间：
2002-11-19
影响因子：
39.2
通讯作者：
Woolf, SH
中科院分区：
文献类型：
--
作者：
Berg, AO;Allan, JD;Woolf, SH
本声明总结了美国预防服务工作组（USPSTF）关于绝经后妇女慢性疾病一级预防使用激素替代疗法的建议，并更新了1996年USPSTF关于该主题的建议。本声明所依据的完整信息，包括证据表和参考文献，可通过USPSTF网站（www.preventiveservices.ahrq.gov）和国家指南交换所（www.guideline.gov）获得。USPSTF审查了绝经后激素替代疗法的使用证据和以下结果：心血管疾病，包括冠心病和中风；骨质疏松和骨折；血栓栓塞;痴呆症与认知功能；乳腺癌、结肠癌、卵巢癌和子宫内膜癌；和胆囊炎。USPSTF还审查了激素替代疗法对植物雌激素、骨质疏松症和心血管疾病影响的证据。使用激素替代疗法来缓解更年期的活跃症状，如潮热、泌尿生殖系统症状、情绪和睡眠障碍等，不在USPSTF建议的范围内，关于这一主题的文献没有进行审查。本建议声明中引用的益处和危害估计的来源在医疗保健研究和质量机构提供的证据摘要中进行了描述。
This statement summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations for use of hormone replacement therapy for the primary prevention of chronic conditions in postmenopausal women and updates the 1996 USPSTF recommendations on this topic. The complete information on which this statement is based, including evidence tables and references, is available through the USPSTF Web site (www.preventiveservices.ahrq.gov) and through the National Guideline Clearinghouse (www.guideline.gov) The USPSTF reviewed the evidence on the use of postmenopausal hormone replacement therapy and the following outcomes: cardiovascular disease, including CHD and stroke; osteoporosis and fractures; thromboembolism; dementia and cognitive function; breast, colon, ovarian, and endometrial cancer; and cholecystitis. The USPSTF also reviewed evidence of the effects of hormone replacement therapy on phytoestrogens and osteoporosis and cardiovascular disease. The use of hormone replacement therapy for relieving active symptoms of menopause, such as hot flashes, urogenital symptoms, and mood and sleep disturbances, among others, is outside the scope of these USPSTF recommendations, and literature on this topic was not reviewed. Sources for estimates of benefits and harms cited in this Recommendation statement are described in the summary of the evidence available from the Agency for Healthcare Research and Quality.